EyeGene Inc - Asset Resilience Ratio

Latest as of September 2025: 41.19%

EyeGene Inc (185490) has an Asset Resilience Ratio of 41.19% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 185490 liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets

₩23.32 Billion

≈ $15.80 Million USD Cash + Short-term Investments

Total Assets

₩56.60 Billion

≈ $38.36 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how EyeGene Inc's Asset Resilience Ratio has changed over time. See EyeGene Inc shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down EyeGene Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 185490 market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩23.32 Billion	41.19%
Total Liquid Assets	₩23.32 Billion	41.19%

Asset Resilience Insights

Very High Liquidity: EyeGene Inc maintains exceptional liquid asset reserves at 41.19% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

EyeGene Inc Industry Peers by Asset Resilience Ratio

Compare EyeGene Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.10%
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	4.52%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	35.56%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for EyeGene Inc (2014–2024)

The table below shows the annual Asset Resilience Ratio data for EyeGene Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	48.52%	₩31.68 Billion ≈ $21.47 Million	₩65.31 Billion ≈ $44.26 Million	-20.07pp
2023-12-31	68.58%	₩53.56 Billion ≈ $36.30 Million	₩78.10 Billion ≈ $52.93 Million	-13.14pp
2022-12-31	81.72%	₩65.69 Billion ≈ $44.52 Million	₩80.38 Billion ≈ $54.47 Million	+1.19pp
2021-12-31	80.54%	₩84.56 Billion ≈ $57.30 Million	₩104.99 Billion ≈ $71.15 Million	+6.18pp
2020-12-31	74.36%	₩33.04 Billion ≈ $22.39 Million	₩44.43 Billion ≈ $30.11 Million	-4.20pp
2019-12-31	78.56%	₩37.17 Billion ≈ $25.19 Million	₩47.31 Billion ≈ $32.06 Million	-7.96pp
2018-12-31	86.52%	₩46.76 Billion ≈ $31.69 Million	₩54.04 Billion ≈ $36.62 Million	+10.89pp
2017-12-31	75.63%	₩22.90 Billion ≈ $15.52 Million	₩30.28 Billion ≈ $20.52 Million	+9.68pp
2016-12-31	65.95%	₩12.24 Billion ≈ $8.29 Million	₩18.56 Billion ≈ $12.58 Million	-5.66pp
2015-12-31	71.61%	₩17.42 Billion ≈ $11.81 Million	₩24.33 Billion ≈ $16.49 Million	+35.39pp
2014-12-31	36.23%	₩2.01 Billion ≈ $1.36 Million	₩5.54 Billion ≈ $3.76 Million	--

pp = percentage points

About EyeGene Inc

KQ:185490 Korea Biotechnology

Market Cap

$29.23 Million

₩43.14 Billion KRW

Market Cap Rank

#23786 Global

#1717 in Korea

Share Price

₩1416.00

Change (1 day)

-1.12%

52-Week Range

₩1193.00 - ₩3630.00

All Time High

₩50300.00